AOD-9604

The AOD-9604 evidence base cited here is 6 sources — 2 clinical, 2 preclinical, 2 regulatory. Its strongest evidence is human — 2 clinical studies, most recently 2014 ("Safety and Metabolism of AOD-9604 as Nutraceutical Ingredient"). Regulatory status: Not FDA-approved (GRAS in AU).

The most useful comparison is against what actually works for weight loss today. This is the context that matters for anyone evaluating AOD-9604 as a fat-loss strategy.

In an era where GLP-1 agonists deliver 15–25% body-weight reduction in large rigorous trials, AOD-9604's modest and ultimately negative clinical results are hard to justify as a primary weight-management approach.

• AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal fat-metabolizing fragment of human growth hormone (residues 176–191) with a tyrosine added at the N-terminus — engineered to isolate HGH's lipolytic effect without its growth-promoting, IGF-1-raising, or diabetogenic effects.
• It is meant to work by upregulating the beta-3 adrenergic receptor (β3-AR) to stimulate fat breakdown (lipolysis) while inhibiting new fat formation (lipogenesis); β3-AR-knockout mice are completely unresponsive, confirming that pathway is essential.
• The most important fact about it: the definitive 24-week Phase IIb obesity trial (n=536) FAILED its primary endpoint — no statistically significant weight loss vs placebo — and the developer terminated obesity development in March 2007.

AOD-9604 ("Anti-Obesity Drug 9604") is a synthetic fragment of the C-terminal region of human growth hormone, designed in 1990s Australia to capture HGH's fat-burning activity without its other hormonal effects. Mechanistically it is elegant — isolate the lipolytic domain, drop the growth-promoting and insulin-antagonistic parts — and the preclinical results were promising.

But the honest headline is efficacy, not mechanism: AOD-9604's largest, most rigorous human trial failed to show meaningful weight loss, and its development as an obesity drug was abandoned in 2007. It appears safe, but the clinical evidence does not support it as an effective fat-loss treatment at the doses studied.

It is not FDA-approved and was declined for compounding in 2024. Everything below is research context synthesized from the published literature — not medical guidance, and not a self-administration protocol.

AOD-9604 is a 16-amino-acid peptide corresponding to HGH residues 176–191, with a tyrosine substituted at the N-terminus. In the 1990s, Frank Ng and colleagues at Monash University (Melbourne) found that this C-terminal fragment carried HGH's lipolytic activity, while the growth-promoting and insulin-antagonistic effects came from different structural regions — so synthesizing just this fragment could, in principle, stimulate fat breakdown without the metabolic complications of full-length GH.

Its sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a disulfide bridge between the cysteines at positions 7 and 14. Molecular formula C78H123N23O23S2, MW ≈ 1,815 g/mol, CAS 221231-10-3. Metabolic Pharmaceuticals Ltd. licensed it and ran clinical development from 2001 to 2007.

There is no FDA-approved dosing — all of the following describes unapproved, off-label use, included for research context only and not as instructions for use.

Community protocols favor a fasted state (≥2 hours since the last meal, often morning after an overnight fast) on the theory that avoiding insulin-mediated suppression maximizes lipolysis. Note the route mismatch: the trials used ORAL dosing, while community use is subcutaneous — which has not been formally studied for safety or efficacy.

Community use is most commonly subcutaneous, though the clinical trials used oral dosing (AOD-9604 showed ~40% oral bioavailability in animal studies). Reported timing is first thing in the morning on an empty stomach, waiting ~20–30 minutes before eating to avoid blunting the lipolytic response with an insulin spike; injection sites are rotated.

A serum half-life of ~4 minutes is widely cited, but no peer-reviewed primary source has been identified for that figure and it may originate from marketing material; downstream metabolic effects are presumed to outlast plasma presence via sustained intracellular lipolytic signaling.

Reported effects are modest relative to approved anti-obesity drugs, and the longer-term data is negative.

• Weeks 1–4: minimal visible change; no significant weight loss expected on available data.
• Weeks 4–8: in the 12-week Phase IIa trial, treated subjects trended toward ~2.6 kg total loss by study end; changes here are incremental and hard to distinguish from normal fluctuation.
• Weeks 8–12: end of a standard cycle; the 12-week trial showed ~1.8 kg average difference between treatment and placebo.
• Beyond 12 weeks: the 24-week Phase IIb trial found NO statistically significant difference vs placebo — effects appear to plateau or vanish over longer durations, the key limitation of the evidence.

AOD-9604's development produced a mixed record: strong preclinical results that did not translate into convincing human efficacy.

Honest assessment: the preclinical promise did not survive rigorous clinical testing. AOD-9604 appears safe, but the evidence does not support it as an effective anti-obesity treatment at the doses studied.

AOD-9604 is sometimes layered with other peptides in body-composition protocols. These combinations are experimental, off-label, and lack clinical validation — research context, not protocol advice.

• With GH secretagogues (CJC-1295 / Ipamorelin) — complementary in theory: AOD-9604 targets lipolysis directly via β3-AR while secretagogues raise endogenous GH for broader metabolic effects (often AOD in the morning fasted, secretagogues before bed).
• With BPC-157 — pairs body-composition aims with tissue repair; BPC-157's anti-inflammatory/healing effects may complement AOD-9604's preliminary cartilage-supportive signal for those with joint issues.
• With other fat-loss agents (tesamorelin, 5-amino-1MQ) — some stack multiple lipolytic agents, though no clinical data supports the combinations and interaction risks are unknown.

AOD-9604 is supplied as a lyophilized powder (commonly 2 mg or 5 mg vials) requiring reconstitution. The following reflects general laboratory peptide handling only.

• Wipe the stopper with alcohol; add bacteriostatic water (0.9% benzyl alcohol) slowly down the vial wall — not onto the powder — and swirl gently until dissolved (do not shake).
• Example: a 5 mg vial + 2.5 mL = 2 mg/mL (200 mcg per 0.1 mL); a 2 mg vial + 1 mL = 2 mg/mL. At 2 mg/mL, a 300 mcg dose = 0.15 mL / 15 units on a U-100 insulin syringe.
• Unreconstituted powder: store at −20°C long-term (2–8°C for shorter periods).
• Reconstituted solution: refrigerate at 2–8°C, protect from light, use within ~3–4 weeks; do not freeze; avoid temperature swings.

AOD-9604 had a favorable safety profile across six clinical trials, with adverse-event rates not significantly different from placebo. Reported effects were mild and transient.

Key limitations: the longest trial was 24 weeks (no data beyond ~6 months), the total population (893) is small for detecting rare events, and — critically — the trials used ORAL dosing, so the subcutaneous route common in community use has never undergone formal safety evaluation. Unregulated product also carries contamination/variability risks separate from the compound itself.

AOD-9604 occupies a complicated regulatory position. For a broader overview of where research peptides sit legally, see the peptide legality guide.

• United States: not FDA-approved as a drug for any indication; obesity development ended in 2007 after the Phase IIb failure. In December 2024 the FDA's Pharmacy Compounding Advisory Committee declined to add AOD-9604 to the 503A bulk-substances list — citing insufficient injectable-route safety data and potential immunogenicity — so it cannot be legally compounded. Available only as a research chemical labeled 'not for human consumption.'
• It separately received GRAS (Generally Recognized As Safe) status as a food ingredient, and a 2014 paper framed it as a 'novel nutraceutical ingredient' — distinct from approval as a therapeutic drug.
• Australia / international: developed in Australia but not approved by the TGA as a therapeutic drug; no regulator worldwide has approved it as a drug. Availability varies, mostly for research use only.

Research-grade AOD-9604 is for laboratory research only and is not intended for human use.

AOD-9604 is prohibited in competitive sport. WADA classifies it under S0 (substances with no current regulatory approval for human therapeutic use), and as a GH fragment it also falls within the scope of S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics); it is banned at all times, in- and out-of-competition. There was brief public confusion in 2013 (an Australian Crime Commission report suggested it wasn't banned), after which WADA issued a formal statement clarifying that AOD-9604 was and remains prohibited. Tested athletes should assume it will trigger an anti-doping violation.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.